FIELD: biotechnology.
SUBSTANCE: invention relates to an anti-human CD79B antibody or an antigen-binding fragment thereof, a method for production thereof, as well as a composition and a conjugate containing same. Also disclosed is a polynucleotide coding an anti-human CD79B antibody, or an antigen-binding fragment thereof, as well as a vector and a host cell containing it.
EFFECT: invention is effective for treating cancer or tumour characterized by CD79B expression.
29 cl, 9 dwg, 4 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES AGAINST CD79b, DRUG CONJUGATES AND THEIR USE | 2019 |
|
RU2805251C2 |
| TUMOR-TARGETING AGONIST CD28 ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2837821C1 |
| ANTIBODY BINDING HUMAN IL-4R, ANTIGEN-BINDING FRAGMENT THEREOF, AND MEDICAL APPLICATION THEREOF | 2019 |
|
RU2779649C1 |
| TUMOR-TARGETED AGONISTIC CD28-ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2808030C2 |
| ANTI-CLDN-18.2 ANTIBODY AND USE THEREOF | 2021 |
|
RU2829997C1 |
| TETANUS TOXIN ANTIBODY AND USE THEREOF | 2020 |
|
RU2815280C1 |
| ANTIBODY CAPABLE OF BINDING TO THYMIC STROMAL LYMPHOPOIETIN, AND USE THEREOF | 2020 |
|
RU2825304C2 |
| ANTI-CLAUDIN 18.2 ANTIBODY AND USE THEREOF | 2020 |
|
RU2822550C2 |
| ANTI-CEACAM6 ANTIBODIES AND USE THEREOF | 2016 |
|
RU2739163C2 |
| ERIBULIN DERIVATIVE DRUG CONJUGATE, METHOD FOR PREPARATION THEREOF AND USE THEREOF IN MEDICINE | 2021 |
|
RU2830242C1 |
